Register Login

CRINETICS PHARMACEUTICALS, INC. (CRNX)

SymbolCRNX
NameCRINETICS PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address10222 BARNES CANYON ROAD,BUILDING NO. 2, SAN DIEGO, California, 92121, United States
Telephone+1 858 450-6464
Fax—
Email—
Websitehttps://www.crinetics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001658247
Description

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Additional info from NASDAQ:
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

2026-05-04 20:26

📋 JEFF KNIGHT (Officer) plans to sell 9K shares of Crinetics Pharmaceuticals, Inc. (at $39.02 each, total $370K) Filed: May 04, 2026 | ID: 003982

Read more
2026-04-29 18:37

New Form SCHEDULE 13G - Crinetics Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0002100119-26-000284 <b>Size:</b> 7 KB

Read more
2026-04-29 17:13

New Form DEF 14A - Crinetics Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001658247-26-000030 <b>Size:</b> 5 MB

Read more
2026-04-27 21:13

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Read more
2026-04-14 20:37

📋 JEFF KNIGHT (Officer) plans to sell 21K shares of Crinetics Pharmaceuticals, Inc. (at $38.66 each, total $808K) Filed: Apr 14, 2026 | ID: 003450

Read more
2026-04-13 20:36

📋 JEFF KNIGHT (Officer) plans to sell 4K shares of Crinetics Pharmaceuticals, Inc. (at $39.44 each, total $175K) Filed: Apr 13, 2026 | ID: 003400

Read more
2026-04-10 20:33

Knight Jeff E. 🟡 adjusted position in 85.2K shares (3 derivative) of Crinetics Pharmaceuticals, Inc. (CRNX) at $40.10 ($6.9M) Transaction Date: Apr 08, 2026 | Filing ID: 024716

Read more
2026-04-10 20:09

(99% Neutral) CRINETICS PHARMACEUTICALS, INC. (CRNX) Announces Executive Departure

Read more
2026-04-08 20:49

📋 JEFF KNIGHT (Officer) plans to sell 85K shares of CRINETICS PHARMACEUTICALS INC (at $38.41 each, total $3.3M) Filed: Apr 08, 2026 | ID: 003337

Read more
2026-04-08 20:05

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07159841 A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-… Phase2 Congenital Adrenal Hyperplasia Recruiting 2026-01-22 2030-03-01 ClinicalTrials.gov
NCT07144163 A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Phase3 Congenital Adrenal Hyperplasia Recruiting 2025-12-11 2027-05-01 ClinicalTrials.gov
NCT07129252 A Study to Investigate Safety and Effectiveness of CRN09682 in Participants Wit… Phase1 SST2-positive Neuroendocrine Neoplasms Recruiting 2025-11-26 2029-08-01 ClinicalTrials.gov
NCT07087054 Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Phase3 Carcinoid Syndrome Recruiting 2025-11-19 2030-01-01 ClinicalTrials.gov
NCT07221084 A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in H… Phase1 Healthy Volunteers Completed 2025-10-28 2026-02-27 ClinicalTrials.gov
NCT06712823 An Extension Study to Evaluate Safety and Efficacy in Participants Treated With… Phase2 Congenital Adrenal Hyperplasia Recruiting 2025-02-25 2027-11-01 ClinicalTrials.gov
NCT05804669 A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing'… Phase1 Cushing Syndrome Recruiting 2023-10-12 2026-10-01 ClinicalTrials.gov
NCT05907291 Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants… Phase2 Congenital Adrenal Hyperplasia Completed 2023-07-03 2025-08-22 ClinicalTrials.gov
NCT05361668 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects … Phase2 Carcinoid Syndrome Completed 2022-04-22 2026-02-24 ClinicalTrials.gov
NCT05192382 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of… Phase3 Acromegaly Active_Not_Recruiting 2021-12-17 2028-01-01 ClinicalTrials.gov
NCT04837040 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of… Phase3 Acromegaly Active_Not_Recruiting 2021-05-12 2027-06-01 ClinicalTrials.gov
NCT06048887 Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers Phase1 Healthy Volunteers Completed 2020-12-18 2022-04-11 ClinicalTrials.gov
NCT04261712 A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Tr… Phase2 Acromegaly Active_Not_Recruiting 2020-01-29 2028-03-01 ClinicalTrials.gov
NCT04246749 Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers Phase1 Healthy Volunteers Completed 2019-09-17 2019-10-25 ClinicalTrials.gov
NCT03936166 A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunte… Phase1 Healthy Volunteers Completed 2019-04-29 2019-12-16 ClinicalTrials.gov
NCT03789656 An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment o… Phase2 Acromegaly Completed 2019-03-12 2020-08-31 ClinicalTrials.gov
NCT03792555 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of… Phase2 Acromegaly Completed 2019-03-11 2020-08-12 ClinicalTrials.gov
NCT03276858 Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers Phase1 Healthy Volunteers Completed 2017-09-22 2018-04-30 ClinicalTrials.gov
Total clinical trials: 18
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo oral capsule Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
Midazolam oral solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
Placebo Oral Solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
CRN00808 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
CRN00808 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04246749
[14C]-CRN00808 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04246749
Placebo Oral Capsule Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
Placebo Oral Solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
CRN01941 Oral Capsule Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
CRN01941 Oral Solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
Placebo Oral Solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06048887
CRN04894 Oral Solution Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06048887
Paltusotine Other Phase PHASE2 Acromegaly COMPLETED NCT03789656
Placebo Other Phase PHASE2 Acromegaly COMPLETED NCT03792555
Paltusotine Other Phase PHASE2 Acromegaly COMPLETED NCT03792555
atumelnant Other Phase PHASE1 Cushing Syndrome RECRUITING NCT05804669
atumelnant (CRN04894) Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT06712823
atumelnant (CRN04894) Other Phase PHASE2 Congenital Adrenal Hyperplasia COMPLETED NCT05907291
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT04837040
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT04837040
CRN09682 Other Phase PHASE1 SST2-positive Neuroendocrine Neoplasms RECRUITING NCT07129252
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07221084
Atumelnant Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07221084
Randomized: 80 mg Paltusotine Other Phase PHASE2 Carcinoid Syndrome COMPLETED NCT05361668
Randomized: 40 mg Paltusotine Other Phase PHASE2 Carcinoid Syndrome COMPLETED NCT05361668
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Paltusotine Other Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Atumelnant Other Phase PHASE3 Congenital Adrenal Hyperplasia RECRUITING NCT07144163
Placebo Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Atumelnant Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Placebo Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE3 Acromegaly ACTIVE_NOT_RECRUITING NCT05192382
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Paltusotine Other Phase PHASE2 Acromegaly ACTIVE_NOT_RECRUITING NCT04261712
Atumelnant DRUG Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
CRN09682 DRUG Phase PHASE1 SST2-positive Neuroendocrine Neoplasms RECRUITING NCT07129252
CRN04894 Oral Solution DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06048887
atumelnant (CRN04894) DRUG Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT06712823
atumelnant DRUG Phase PHASE1 Cushing Syndrome RECRUITING NCT05804669
Randomized: 80 mg Paltusotine DRUG Phase PHASE2 Carcinoid Syndrome COMPLETED NCT05361668
Randomized: 40 mg Paltusotine DRUG Phase PHASE2 Carcinoid Syndrome COMPLETED NCT05361668
[14C]-CRN00808 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04246749
Placebo Oral Capsule DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
CRN01941 Oral Capsule DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
CRN01941 Oral Solution DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03936166
Placebo DRUG Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07159841
Paltusotine DRUG Phase PHASE3 Carcinoid Syndrome RECRUITING NCT07087054
Placebo oral capsule DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
Midazolam oral solution DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03276858
Placebo Oral Solution DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06048887
CRN00808 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04246749
Total products: 116